| Similar Articles |
|---|
 |
American Family Physician
March 15, 2005
Lockman et al. |
Treatment of Cholesterol Abnormalities The relationship between coronary heart disease and elevated cholesterol levels has been recognized for many years, but now studies show an improvement in patient-oriented outcomes in patients receiving drug therapy.   |
BusinessWeek
April 19, 2004
Catherine Arnst |
Cholesterol: How Low Should It Be? New studies say as low as possible, but drugs aren't for everybody |
American Family Physician
January 15, 2001
Michael A. Crouch |
Effective Use of Statins to Prevent Coronary Heart Disease Primary and secondary prevention trials have shown that use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (also known as statins) to lower an elevated low-density lipoprotein level can substantially reduce coronary events and death from coronary heart disease... |
American Family Physician
January 15, 2002
Lori J. Mosca |
Optimal Management of Cholesterol Levels and the Prevention of Coronary Heart Disease in Women Elevated levels of low-density lipoprotein cholesterol and triglycerides and low levels of high-density lipoprotein cholesterol are significant risk factors for coronary heart disease. Abundant data show inadequate utilization of lipid-lowering therapy in women... |
American Family Physician
March 1, 2002
Richard S. Safeer |
Cholesterol Treatment Guidelines Update In addition to modifying current strategies of risk assessment, the new guidelines stress the importance of an aggressive therapeutic approach in the management of hypercholesterolemia... |
Chemistry World
September 18, 2015
Rebecca Trager |
Amgen expands cardiovascular portfolio with Dezima acquisition Dezima's lead molecule is the cholesterol-lowering drug TA-8995. |
The Motley Fool
December 23, 2003
Arash Mostaghimi |
The Cholesterol Wars Who will win the fight to save your arteries? Fortunately for our corpulent country, pharmaceutical companies want to unclog our arteries -- and lighten our wallets. But which pharma stock will add to most girth to a portfolio? |
The Motley Fool
December 4, 2006
Michael P. Cecil |
Pfizer's Cholesterol-Drug Hopes Crumble In surprising and disappointing news, the pharma's promising new drug fails clinical trials. With Pfizer shares declining because of the bad news, is now a good time to buy? |
HHMI Bulletin
May 2011
Sarah C. P. Williams |
The Next Statin Although clinicians have firmly established the link between cholesterol levels and heart disease, there are still more questions than answers when it comes to the nitty-gritty molecular details of this connection. |
American Family Physician
July 15, 2005
Lee Radosh |
STEPS: Colesevelam (WelChol) for Reduction of LDL Cholesterol Colesevelam lowers LDL cholesterol levels a small amount (7% to 16%) when used alone and provides additional cholesterol lowering when added to statin therapy. |
BusinessWeek
August 2, 2004
Carol Marie Cropper |
Cholesterol Drugs: Not So Fast Do you have high low-density lipoprotein? A C-reactive protein test may help your doctor decide if it poses a threat. |
American Family Physician
December 15, 2000
Alan J. Garber |
Attenuating Cardiovascular Risk Factors in Patients with Type 2 Diabetes All cardiovascular risk factors except smoking are more prevalent in patients with type 2 diabetes. In addition to exercise, weight control, aspirin therapy and blood pressure control, therapy to modify lipid profiles is usually necessary... |
The Motley Fool
November 15, 2011
Brian Orelli |
Good Data, Big Drug Market, but Still Risky Eli Lilly's evacetrapib is behind Roche and Merck. |
Chemistry World
May 2008
Derek Lowe |
In the pipeline The controversy over cholesterol drug Vytorin has been going on for months. Surveying the wreckage, my first thought is: what a terrible shame the whole affair is. |
American Family Physician
June 15, 2005
Hanna & Wenger |
Secondary Prevention of Coronary Heart Disease in Elderly Patients A review of the scientific evidence for the secondary prevention of coronary heart disease in the elderly. |
Nurse Practitioner
July 2010
Kristine A. Scordo |
Treating antiretroviral-induced dyslipidemia in HIV-infected adults Studies indicate that HIV-infected patients (both males and females) may be at an increased risk for the development of cardiovascular disease |
| AskMen.com |
Cholesterol & The Prostate A new study suggests that men may be able to lower their risk of getting the most aggressive form of prostate cancer by keeping their cholesterol in a healthy range. |
BusinessWeek
March 11, 2010
Ellen Gibson |
The Quest to Boost Good Cholesterol Cleveland Clinic's Steven Nissen is again pursuing a drug that will attack plaque by raising HDL. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Hyperlipidemia: The Anti-CETPs Redux The crowded cholesterol-control category is the biggest US drug market, with 2010 global sales close to $35 billion, according to IMS Health. |
Scientific American
April 2005
Diane Martindale |
Reactive Reasoning Is an inflammation protein the next cholesterol? |
The Motley Fool
November 16, 2009
Brian Orelli |
Abbott Puts a Nail in Merck's Coffin There's a clear winner from the American Heart Association conference. |
BusinessWeek
November 24, 2010
Tom Randall |
Merck May Have a Cholesterol Winner Merck told doctors at the American Heart Assn. annual meeting that new data showed its drug anacetrapib had reduced bad cholesterol by 40 percent while raising good cholesterol by an unprecedented 138 percent. |
Nutrition Action Healthletter
October 2001 |
Read My Lipids How to lower your risk of a heart attack... |
Chemistry World
August 27, 2015
Phillip Broadwith |
Drugs in a class of their own In the last month, three drugs in new therapeutic classes have been approved for cardiovascular diseases. |
Pharmaceutical Executive
February 1, 2009
Walter Armstrong |
Brand of the Year: Crestor For aiming to be a game-changer in cardiovascular disease, we recognize comeback kid Crestor as the year's No. 1. Plus three fine finalists. |
The Motley Fool
December 30, 2003
Arash Mostaghimi |
Turning Cholesterol Into Cash With 62 million Americans suffering from heart disease, it's a huge target for major drug makers. |
BusinessWeek
January 17, 2008
John Carey |
In the Real World, a Slew of Side Effects from Statins In clinical trials of statins, side effects were relatively rare. But many doctors believe they are more common in the real world. |
American Family Physician
April 15, 2003 |
Cholesterol What is cholesterol?... Why is a high cholesterol level unhealthy?... When should I start having my cholesterol level checked?... Are there different kinds of cholesterol?... What can I do to improve my cholesterol level?... etc. |
Health
January 2008
Jessica Snyder Sachs |
What You Must Know About Your Cholesterol Many of us are in the danger zone, and we don't realize it. What can we start to do right now to change that? |
American Family Physician
October 15, 2003
Morris & Tiller |
Ezetimibe for Hypercholesterolemia Ezetimibe is safe and effective for lowering LDL cholesterol and triglyceride levels, but has not been shown to affect patient-oriented outcomes. |
BusinessWeek
December 13, 2004
Kate Murphy |
Cholesterol: The Bigger the Better Many doctors are convinced that getting a more thorough cholesterol test, one that identifies the types of LDL particles, can improve treatment and save lives. |
American Family Physician
October 15, 2003
Gavin et al. |
Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes By increasing patient awareness of the link between diabetes and heart disease, family physicians can encourage patients to take medications (including aspirin), stop smoking, lower blood pressure, and lower cholesterol and blood glucose levels. |
Chemistry World
January 2007
Derek Lowe |
Opinion: In the Pipeline Here is a look at the recent failure of Pfizer's cholesterol drug, torcetrapib, and what it could mean for the future of pharmaceutical research. |
Chemistry World
May 28, 2012
Sarah Houlton |
HDL drug class struggling after latest flop The failure of dalcetrapib, a drug from Roche designed to raise HDL, or 'good', cholesterol, has turned the spotlight again on such drugs. |
The Motley Fool
April 2, 2008
Michael P. Cecil |
Irrational Exuberance for Vytorin and Zetia? Drugmakers Merck and Schering-Plough certainly hoped data from the Enhance study would enhance the value and status of their blockbuster cholesterol-fighting drugs Zetia and Vytorin -- but its results did quite the opposite. |
BusinessWeek
November 22, 2004
Barrett & Carey |
Wondering About A Wonder Drug While the benefits of statins, sold under names such as Lipitor and Zocor, are well established, some doctors argue that their side effects have not received adequate scrutiny. |
BusinessWeek
November 29, 2004
Catherine Arnst |
Big Pharma's Blinders Hugely profitable thanks to a few blockbusters, Big Pharma is far too focused on looking for the next best-seller, causing companies to pass up opportunities to deliver important breakthroughs. |
Nursing Management
August 2008
Jill R. Quinn |
Women and Heart Disease: An Update A look at statistics regarding coronary heart disease in women as well as related risk factors and prevention. |
American Family Physician
January 15, 2001 |
Goals for Lowering Your Cholesterol Why is it important to have a normal cholesterol level?... What does the term "total cholesterol" mean?... Why is LDL called the "bad" cholesterol?... What are normal cholesterol levels?... How can I reduce my LDL and total cholesterol levels?... etc. |
Managed Care
November 2004
Martin Sipkoff |
OTC Status for Low-Dose Lovastatin Would Have Widespread Implications The FDA stands poised to approve OTC low-dose statins, following a similar change in United Kingdom. |
The Motley Fool
December 1, 2009
Robert Steyer |
Merck Makes a Mark on Good Cholesterol Can't profit from fighting bad lipoproteins? Start boosting the good ones. |
American Family Physician
October 15, 2006
Sharonne N. Hayes |
Preventing Cardiovascular Disease in Women The American Heart Association guidelines for cardiovascular disease prevention in women provide physicians with a clear plan for assessment and treatment of cardiovascular disease risk and personalization of treatment recommendations. |
The Motley Fool
January 27, 2004
David Nierengarten |
Pfizer's Next Target? Esperion, swallowed by Pfizer last year, shares many similarities with Atherogenics. Investors in the latter, however, should not count on being acquired any time soon by a big pharmaceutical company. |
The Motley Fool
November 22, 2010
Brian Orelli |
Let's Call It a Partial Victory Merck's Vytorin works better than a placebo. Unfortunately, it may be too little and too late to do anything about the sales cut that Vytorin has taken over the past few years. |
Nurse Practitioner
February 2012
Wood & Gordon |
Preventing CVD in women: The NP's role This article focuses on the new American Heart Association guidelines for preventing cardiovascular disease in women and the nurse practitioner's role in implementing them. |
Chemistry World
January 19, 2009
Manisha Lalloo |
Synthetic HDL could boost body's 'good cholesterol' US scientists say gold nanoparticle based therapies could be used to help boost levels of good cholesterol in our bodies. |
Nutrition Action Healthletter
April 1999 |
Cholestin Lowers Cholesterol It may be made from red yeast grown on rice, but over-the-counter Cholestin lowers blood cholesterol about as much as Mevacor and other prescription "statin" drugs...at about one-fifth the cost... |
American Family Physician
April 1, 2001
Joan Bedinghaus |
Coronary Artery Disease Prevention: What's Different for Women? Cardiovascular disease is the leading cause of death in women, as well as an important cause of disability, although many women and their physicians underestimate the risk... |
The Motley Fool
September 24, 2010
Brian Orelli |
Prepare for This $12 Billion Whoosh Pfizer's Lipitor is the top-selling cholesterol drug -- in fact, it's the top selling drug period -- but it'll start to see generic competition in a little over a year. |
Nutra Solutions
July 1, 2005 |
Lowered LDL Study finds that subjects with moderately high cholesterol experienced a 6% drop in total cholesterol after taking a 5g daily dose of an immunoglobulin protein isolate over a period of three weeks. |
